UCB

Bepranemab

This study assesses Bepranemab, an anti-tau antibody treatment aiming to modify the course of Alzheimer’s by targeting tau pathology. It explores the drug’s impact on improving cognitive outcomes in individuals with early Alzheimer’s disease and Mild Cognitive Impairment (MCI).

Status: ACTIVE, NOT RECRUITING

Study Details

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.